Related Experiment Videos
Hypertension and CHD risk: whither alpha-1 blockers?
1Department of Cardiology, Dr Babasaheb Ambedkar Memorial Hospital, Bombay.
Indian Heart Journal
|May 1, 1996
Summary
Selective alpha-1 blockers are now first-line hypertension treatments, comparable in efficacy and tolerability to other agents. They offer additional benefits, including improved cardiovascular risk factors like cholesterol and glucose levels.
Area of Science:
- Pharmacology and Cardiovascular Medicine
Background:
- Alpha-blockers are now recommended as first-line agents for hypertension management.
- Selective alpha-1 blockers target alpha-1 receptors to reduce peripheral vascular resistance.
Purpose of the Study:
- To evaluate the antihypertensive efficacy and tolerability of selective alpha-1 blockers.
- To investigate the additional benefits of selective alpha-1 blockers on coronary heart disease (CHD) risk factors.
Main Methods:
- Comparison of antihypertensive efficacy with other major drug classes.
- Assessment of tolerability in clinical practice, referencing the TOMHS study.
- Evaluation of effects on serum lipids, glucose levels, and left ventricular hypertrophy.
Main Results:
- Antihypertensive efficacy is comparable to other major antihypertensive agents.
- Tolerability is similar to other commonly used antihypertensive drugs.
- Beneficial effects include reduction in total cholesterol, increase in HDL cholesterol, improved insulin sensitivity, lower blood glucose, and regression of left ventricular hypertrophy.
Conclusions:
- Selective alpha-1 blockers are effective and well-tolerated first-line treatments for hypertension.
- These agents offer significant advantages by improving multiple CHD risk factors.
- The favorable lipid and glucose profiles make selective alpha-1 blockers an increasingly valuable therapeutic option.